These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15863265)

  • 1. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
    Reinecke P; Kalinski T; Mahotka C; Schmitz M; Déjosez M; Gabbert HE; Gerharz CD
    Cancer Lett; 2005 May; 222(2):165-71. PubMed ID: 15863265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
    Fan S; Cherney B; Reinhold W; Rucker K; O'Connor PM
    Clin Cancer Res; 1998 Apr; 4(4):1047-54. PubMed ID: 9563901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of taxol in human head and neck tumors.
    Gan Y; Wientjes MG; Schuller DE; Au JL
    Cancer Res; 1996 May; 56(9):2086-93. PubMed ID: 8616855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
    Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
    Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types.
    Reinecke P; Schmitz M; Schneider EM; Gabbert HE; Gerharz CD
    Cancer Invest; 2000; 18(7):614-25. PubMed ID: 11036469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines.
    Lui WY; Chang YF; Li LL; Ho LK; Su TL; Chen JY; Liu TY; P'Eng FK; Chi CW
    Anticancer Res; 1998; 18(5A):3339-45. PubMed ID: 9858906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas.
    Heikaus S; Casliskan E; Mahotka C; Gabbert HE; Ramp U
    Apoptosis; 2007 Sep; 12(9):1645-57. PubMed ID: 17610067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
    Shang D; Ito N; Kamoto T; Ogawa O
    Urology; 2007 May; 69(5):1007-12. PubMed ID: 17482960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines.
    Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
    Int J Oncol; 2005 Jun; 26(6):1563-7. PubMed ID: 15870870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
    Vasey PA; Jones NA; Jenkins S; Dive C; Brown R
    Mol Pharmacol; 1996 Dec; 50(6):1536-40. PubMed ID: 8967975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of bcl-2 gene family in taxol-mediated apoptosis in BJAB B cell lymphoma cell line].
    Zhou X; Xu L; He K
    Zhonghua Zhong Liu Za Zhi; 2000 Nov; 22(6):453-5. PubMed ID: 11235561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines.
    Faried A; Faried LS; Kimura H; Sohda M; Nakajima M; Miyazaki T; Kato H; Kanuma T; Kuwano H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):301-8. PubMed ID: 16028102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.
    Ramp U; Dejosez M; Mahotka C; Czarnotta B; Kalinski T; Wenzel M; Lorenz I; Müller M; Krammer P; Gabbert HE; Gerharz CD
    Br J Cancer; 2000 Jun; 82(11):1851-9. PubMed ID: 10839301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
    Shang D; Ito N; Watanabe J; Awakura Y; Nishiyama H; Kamoto T; Ogawa O
    Eur Urol; 2007 Oct; 52(4):1131-9. PubMed ID: 17275163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
    Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
    Int J Cancer; 1996 May; 66(3):322-5. PubMed ID: 8621251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
    Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro.
    Jaakkola M; Rantanen V; Grénman S; Kulmala J; Grénman R
    Anticancer Res; 1997; 17(2A):939-43. PubMed ID: 9137431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma.
    Sun CQ; Arnold R; Fernandez-Golarz C; Parrish AB; Almekinder T; He J; Ho SM; Svoboda P; Pohl J; Marshall FF; Petros JA
    Cancer Res; 2006 Sep; 66(17):8542-9. PubMed ID: 16951166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O; Arce F; Gätjens-Boniche O; Díaz C
    Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.